Is Anteris Technologies Global Corp. (AVR) a Buy, Sell, or Hold?
NASDAQ : AVR
Anteris Technologies Global Corp.
$7.9541 USD
-$0.29 (-3.47%)
- Volume
- 368.01K
- Average Volume
- 1.24M
- Market Capitalization
- $292.62M
- P/E Ratio
- -1.99
- Dividend Yield
- 0.00%
- Price Target
- $18.00
- Year High
- $11.06
- Year Low
- $2.99
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $20.93
Company Overview
NASDAQ
Wayne Geoffrey Paterson
Medical - Devices
Healthcare
AVR
174
US
USD
Liquidity Metrics
0.01
20.93
20.93
20.68
0.00
Sales & Valuation
$1.91M
158.09
0.67
-3.38
-3.68
Profitability
-$4
-$94.14M
-5148.78%
-5116.15%
-124.40%
-32.34%
P/E Metrics
-1.99
0.06
0.06
Analyst Price Target & Rating
$18.00
$18.00
$18.00
2/5
2 Analysts
-55.81%
Financial Health Scores
8.88
3/9
$272.98M
$294.72M
$16.31M
-$94.63M
Key Metrics (TTM)
$23.66M
12.78
-0.25
20.93
-124.40%
-34.04%
-49.06%
-28.60%
-963 days
Company Executives
| Name | Title |
|---|---|
| David Denis | President & Director |
| Chris Meduri | Chief Medical Officer & Member of Medical Advisory Board |
| Matthew McDonnell | Chief Financial Officer |
| Wayne Geoffrey Paterson | Vice Chairman & Chief Executive Officer |
Poll Results
No votes yet today — be the first to share your view!
About Anteris Technologies Global Corp. (NASDAQ:AVR) Stock
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatu ... s, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Pennon returns to profit after water bill hikes
2026-06-10 03:51:00
Pennon Group PLC (LSE:PNN, OTC:PEGRY) returned to the black in its latest financial as higher regulatory allowances and increased water consumption boosted...
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
2026-06-08 06:00:00
MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This authorization marks a significant milestone in the Company's clinical and regulatory strategy and enables patient recruitment to commence at leading centers in France.
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
2026-05-13 08:39:00
MINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced the appointment of Ms. Susan Knight and Mr.
Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy
2026-05-13 07:48:00
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has strengthened its board with the appointments of experienced healthcare and finance executive Susan...
Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push
2026-05-13 06:43:00
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported strong operational progress for the March 2026 quarter as the company advanced recruitment...
Anteris Announces Results for the First Quarter of 2026
2026-05-12 19:00:00
MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.
Anteris Announces Results for the First Quarter of 2026
2026-05-12 19:00:00
MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. Q1 2026 Highlights Completed aggregate capital raises totalling $320 million in January 2026 to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR® THV System Advanced PARADIGM Trial recruitment, supported by ongoing regulatory and operational work to activate additional countries and sites – post quarter-end, U.S. enrollment commenced Presented clinical data from the ongoing EMBARK Study and U.S. Early Feasibility Study (EFS) at Cardiovascular Research Technologies (CRT 2026) and Sydney Valves 2026, supporting ongoing scientific engagement and exchange with the clinical community “Q1 2026 reflects strong execution across the PARADIGM Trial, with patient enrollment ongoing in Europe and continued progress on key recruitment activities globally.
Whirlpool cuts forecast, suspends dividend as Iran war hammers demand
2026-05-07 08:22:00
Whirlpool Corporation (NYSE:WHR) reported a steep first-quarter loss and slashed its full-year outlook, citing rapid deterioration in macroeconomic...
Frequently Asked Questions
-
What is the current Anteris Technologies Global Corp. (AVR) stock price?
-
Anteris Technologies Global Corp.(NASDAQ:AVR) stock price is $7.9541 in the last trading session. During the trading session, AVR stock reached the peak price of $11.055 while $2.99 was the lowest point it dropped to. The percentage change in AVR stock occurred in the recent session was --3.47% while the dollar amount for the price change in AVR stock was -$0.29.
-
AVR's industry and sector of operation?
-
The NASDAQ listed AVR is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of AVR?
-
David Denis | President & Director
Chris Meduri | Chief Medical Officer & Member of Medical Advisory Board
Matthew McDonnell | Chief Financial Officer
Wayne Geoffrey Paterson | Vice Chairman & Chief Executive Officer
| -
How many employees does AVR have?
-
Number of AVR employees currently stands at 174. AVR operates from 860 Blue Gentian Road, Suite 340, Eagan, MN 55121, US.
-
Link for AVR official website?
-
Official Website of AVR is: https://anteristech.com
-
How do I contact AVR?
-
AVR could be contacted at phone #61 13 0055 0310 and can also be accessed through its website. AVR operates from 860 Blue Gentian Road, Suite 340, Eagan, MN 55121, US.
-
How many shares of AVR are traded daily?
-
The average number of AVR shares traded daily for last 3 months was 1.24M.
-
What is the market cap of AVR currently?
-
The market value of AVR currently stands at $292.62M with its latest stock price at $7.9541